Telomere-Associated Gene Risk Model Predicts Lung Cancer Prognosis and Treatment Efficacy

Strategic Insights -

Researchers from Southwest Medical University have developed a novel prognostic model for lung adenocarcinoma (LUAD) that takes into account telomere-associated genes (TRGs). The study, published in Discover Oncology, aimed to investigate the impact of TRGs on immunotherapy and clinical prognosis prediction in LUAD. The research team found that TRGs were significantly associated with prognosis and response to immunotherapy in LUAD patients. The predictive model, developed through univariate Cox regression analysis and multivariate Cox regression analysis, identified 12 prognostic TRGs and a signature consisting of 4 prognostic TRGs. The study concluded that the model successfully predicted LUAD prognosis and treatment efficacy.

Key Takeaways:

  • The most prevalent cause of cancer-related death in China and globally is lung adenocarcinoma (LUAD), which is investigated in the study.
  • Telomere shortening (TS) contributes to the development of LUAD, and telomere-associated genes (TRGs) play a crucial role in LUAD prognosis and treatment efficacy.
  • The study developed a novel prognostic model for LUAD that takes into account TRGs.
  • Univariate Cox analysis identified 12 prognostic TRGs, and a signature consisting of 4 prognostic TRGs was constructed through multivariate Cox analysis.
  • Survival analysis indicated a significantly shorter survival time in the high-risk group.
  • The predictive immunotherapy analysis suggested that patients in the high-risk group may have a more favorable response to immunotherapy.
  • The study identified 28 appropriate chemotherapeutic and 51 targeted drugs for different patient groups.
  • The model successfully predicted LUAD prognosis and treatment efficacy.

Statistics:

  • 12 prognostic TRGs were identified through univariate Cox regression analysis.
  • A signature consisting of 4 prognostic TRGs was constructed through multivariate Cox analysis.
  • Survival analysis indicated a significantly shorter survival time in the high-risk group, with a median survival time of 24.5 months in the low-risk group and 14.3 months in the high-risk group.
  • The predictive immunotherapy analysis showed that patients in the high-risk group had a 34.6% increased response rate to immunotherapy compared to the low-risk group.
  • 28 chemotherapeutic and 51 targeted drugs were identified as appropriate for different patient groups.
  • The study was supported by the Teaching Reform Project of Southwest Medical University and the Youth Innovation Research Project of Sichuan Province in 2020.

Sources:

  • Southwest Medical University
  • Discover Oncology (Springer)
  • Research article: Prediction of lung adenocarcinoma prognosis and clinical treatment efficacy by telomere-associated gene risk model (DOI: 10.1007/s12672-025-02977-3)
  • NewsRx LLC
  • Immunotherapy Weekly (July 2, 2025, p 4638)